7587-15-7

Basic information

• Product Name: 2,5-dichloro-4-iodophenol
• Synonyms: 2,5-dichloro-4-iodophenol;Einecs 231-495-3;Phenol, 2,5-dichloro-4-iodo-
• CAS NO: 7587-15-7
• Molecular Formula: C₆H₃Cl₂IO
• Molecular Weight: 288.89789
• EINECS: 231-495-3
• Mol File: 7587-15-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 299.9°C at 760 mmHg
• Flash Point: 135.2°C
• Appearance: /
• Density: 2.158g/cm³
• Vapor Pressure: 0.000651mmHg at 25°C
• Refractive Index: 1.684
• CAS DataBase Reference: 2,5-dichloro-4-iodophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-dichloro-4-iodophenol(7587-15-7)
• EPA Substance Registry System: 2,5-dichloro-4-iodophenol(7587-15-7)

Safety Data

• Hazardous Substances Data: 7587-15-7(Hazardous Substances Data)

Usage

Composition

Organic compound containing a phenol ring with two chlorine atoms and one iodine atom attached.

Common Uses

Building block in synthesis of pharmaceutical and agrochemical products.
Intermediate in manufacturing dyes and other organic compounds.

Reactivity and Versatility

Known for high reactivity and versatility in chemical reactions.

Handling Precautions

Requires careful handling due to potential hazards if not managed properly.

InChI:InChI=1/C6H3Cl2IO/c7-3-2-6(10)4(8)1-5(3)9/h1-2,10H

Upstream product

• 583-78-8 2,5-dichlorophenol 

Downstream Products

• 26051-15-0 Cyclopropancarbonsaeure-2',5'-dichlor-4'-iodphenylester 
• 208512-74-7 dimethyl-thiocarbamic acid O-(2,5-dichloro-4-iodo-phenyl) ester 
• 208512-75-8 dimethyl-thiocarbamic acid S-(2,5-dichloro-4-iodo-phenyl) ester 
• 208512-76-9 2,3-dichloro-4-iodothiophenol 
• 208512-77-0 (2,5-dichloro-4-iodo-phenylsulfanyl)-acetic acid methyl ester 
• 208512-45-2 (E)-3-(2,5-Dichloro-4-methoxycarbonylmethylsulfanyl-phenyl)-acrylic acid 
• 208512-39-4 3-(4-carboxymethylsulfanyl-2,5-dichloro-phenyl)-acrylic acid tert-butyl ester 
• 208512-43-0 3-(2,5-dichloro-4-methoxycarbonylmethylsulfanyl-phenyl)-acrylic acid tert-butyl ester 
• 208512-47-4 (E)-3-(2,5-Dichloro-4-methoxycarbonylmethylsulfanyl-phenyl)-acrylic acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 208512-49-6 {4-[2-(tert-butoxycarbonylmethyl-carbamoyl)-vinyl]-2,5-dichloro-phenylsulfanyl}-acetic acid methyl ester 
• 307002-20-6 2-({4-[(1E)-2-{[2-(tert-butoxy)-2-oxoethyl]carbamoyl}eth-1-en-1-yl]-2,5-dichlorophenyl}sulfanyl)acetic acid 
• 208512-83-8 (6R,7R)-7-{2-[4-((E)-2-Carboxy-vinyl)-2,5-dichloro-phenylsulfanyl]-acetylamino}-3-chloromethyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 
• 208512-82-7 (6R,7R)-7-{2-[4-((E)-2-tert-Butoxycarbonyl-vinyl)-2,5-dichloro-phenylsulfanyl]-acetylamino}-3-chloromethyl-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 307002-27-3 diphenylmethyl (6R,7R)-7-[2-({4-[(1E)-2-{[2-(tert-butoxy)-2-oxoethyl]carbamoyl}eth-1-en-1-yl]-2,5-dichlorophenyl}sulfanyl)acetamido]-3-(chloromethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 

Relevant articles and documents

A high temperature investigation using microwave synthesis for electronically and sterically disfavoured substrates of the Newman-Kwart rearrangement

Electronically deactivated and/or sterically hindered substrates undergo the Newman-Kwart rearrangement (NKR) at around 300 °C, beyond the range of most convenient and safe, small-scale laboratory equipment. We report here the convenient conversions of several difficult substrates using modern microwave technology, which has proven ideal for investigating this high temperature reaction in all but the?most refractory of cases. In addition, several previously reported difficult examples were re-investigated, and found not to require high temperatures under these conditions, for various reasons which are elaborated upon.

Cephalosporin derivatives

The present invention provides a novel series of cephem derivatives of the general formula I wherein R1, R2, R3, R5, R6, R7, A, L1, X, n and n′ are as defined herein above. The compounds of formula I are antibacterial agents useful in the treatment of infections in humans and other animals caused by a variety of gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus. Also included in the invention are processes for preparing the compounds of formula I and pharmaceutical compositions containing said compounds in combination with pharmaceutically acceptable carriers, diluents or excipients.